- call +1-201-465-4211
- email sales@mrinsights.biz
Urology is a branch of medicine that deals with the health of the urinary tract and reproductive tract in men and women. Urologic diseases or conditions include infection in the urinary tract, bladder control problems, kidney stones and prostate problems, among others. The prostate gland surrounds the urethra, the tube that carries urine from the bladder out of the body. Benign prostatic hyperplasia (BPH) is an enlarged prostate, which increases the size of the prostate gland. As the prostate gets enlarged, it may squeeze or partly block the urethra, resulting in significantly blocking urine flow. BPH is normal in the aging process of a male, caused by changes in hormone balance and cell-growth.
Scope of the Report:
This report focuses on the Benign Prostatic Hyperplasia (BPH) Drugs in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
The increasing demand for Benign Prostatic Hyperplasia (BPH) Drugs drives the market. Three factors contributing to the growth of the global benign prostatic hyperplasia drugs market are growing geriatric male population, strong r&d and growing demand for alpha-blockers. The evolution of alpha-blockers therapy for BPH has focused on improving convenience and tolerability. Reversing signs and symptoms or preventing progression of the disease are the indications of treating BPH. Alpha-blockers are the most effective, least costly, and best tolerated of the drugs for relieving LUTS. Additionally, one driver in market is growing geriatric male population. The presence of a large population with BPH symptoms is expected to drive the market growth. The risk of BPH increases exponentially with the rise in the age of an individual. Approximately, 80% of men who reach 60 years and above have mild to strong symptoms of BPH. This disorder affects one in 38 individuals in the age group of 40-59 years; however, in the age group of 60-69 years, it affects one in 14 individuals. The BPH drugs market in the Americas accounted for the majority market share during 2016 and the market in this region is likely to experience a high growth rate during the estimated period. Factors such as the growing demand for urology-related disorders and the increasing rate of geriatric men population, will stimulate the demand for BPH drugs and fuel the market’s growth.
The worldwide market for Benign Prostatic Hyperplasia (BPH) Drugs is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study.
Market Segment by Manufacturers, this report covers
Astellas Pharma
Eli Lilly
GlaxoSmithKline
Sanofi
ADC Therapeutics
Bayer HealthCare
Bristol-Myers Squibb
Valeant Pharmaceuticals
Endo Pharmaceuticals
Foresee Pharmaceuticals
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Alpha-Blocker
Phosphodiesterase Type-5 Inhibitors
5-Alpha-Reductase Inhibitors
Market Segment by Applications, can be divided into
Men
Women
There are 15 Chapters to deeply display the global Benign Prostatic Hyperplasia (BPH) Drugs market.
Chapter 1, to describe Benign Prostatic Hyperplasia (BPH) Drugs Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Benign Prostatic Hyperplasia (BPH) Drugs, with sales, revenue, and price of Benign Prostatic Hyperplasia (BPH) Drugs, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Benign Prostatic Hyperplasia (BPH) Drugs, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Benign Prostatic Hyperplasia (BPH) Drugs market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Benign Prostatic Hyperplasia (BPH) Drugs sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Market Overview
1.1 Benign Prostatic Hyperplasia (BPH) Drugs Introduction
1.2 Market Analysis by Type
1.2.1 Alpha-Blocker
1.2.2 Phosphodiesterase Type-5 Inhibitors
1.2.3 5-Alpha-Reductase Inhibitors
1.3 Market Analysis by Applications
1.3.1 Men
1.3.2 Women
1.4 Market Analysis by Regions
1.4.1 North America (United States, Canada and Mexico)
1.4.1.1 United States Market States and Outlook (2013-2023)
1.4.1.2 Canada Market States and Outlook (2013-2023)
1.4.1.3 Mexico Market States and Outlook (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy)
1.4.2.1 Germany Market States and Outlook (2013-2023)
1.4.2.2 France Market States and Outlook (2013-2023)
1.4.2.3 UK Market States and Outlook (2013-2023)
1.4.2.4 Russia Market States and Outlook (2013-2023)
1.4.2.5 Italy Market States and Outlook (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.3.1 China Market States and Outlook (2013-2023)
1.4.3.2 Japan Market States and Outlook (2013-2023)
1.4.3.3 Korea Market States and Outlook (2013-2023)
1.4.3.4 India Market States and Outlook (2013-2023)
1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)
1.4.4 South America, Middle East and Africa
1.4.4.1 Brazil Market States and Outlook (2013-2023)
1.4.4.2 Egypt Market States and Outlook (2013-2023)
1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)
1.4.4.4 South Africa Market States and Outlook (2013-2023)
1.4.4.5 Nigeria Market States and Outlook (2013-2023)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Astellas Pharma
2.1.1 Business Overview
2.1.2 Benign Prostatic Hyperplasia (BPH) Drugs Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.2 Eli Lilly
2.2.1 Business Overview
2.2.2 Benign Prostatic Hyperplasia (BPH) Drugs Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.3 GlaxoSmithKline
2.3.1 Business Overview
2.3.2 Benign Prostatic Hyperplasia (BPH) Drugs Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.4 Sanofi
2.4.1 Business Overview
2.4.2 Benign Prostatic Hyperplasia (BPH) Drugs Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.5 ADC Therapeutics
2.5.1 Business Overview
2.5.2 Benign Prostatic Hyperplasia (BPH) Drugs Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.6 Bayer HealthCare
2.6.1 Business Overview
2.6.2 Benign Prostatic Hyperplasia (BPH) Drugs Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.7 Bristol-Myers Squibb
2.7.1 Business Overview
2.7.2 Benign Prostatic Hyperplasia (BPH) Drugs Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.8 Valeant Pharmaceuticals
2.8.1 Business Overview
2.8.2 Benign Prostatic Hyperplasia (BPH) Drugs Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.9 Endo Pharmaceuticals
2.9.1 Business Overview
2.9.2 Benign Prostatic Hyperplasia (BPH) Drugs Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.10 Foresee Pharmaceuticals
2.10.1 Business Overview
2.10.2 Benign Prostatic Hyperplasia (BPH) Drugs Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
3 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Market Share and Competition by Manufacturer (2016-2017)
3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales and Market Share by Manufacturer (2016-2017)
3.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Market Share by Manufacturer (2016-2017)
3.3 Market Concentration Rate
3.3.1 Top 3 Benign Prostatic Hyperplasia (BPH) Drugs Manufacturer Market Share in 2017
3.3.2 Top 6 Benign Prostatic Hyperplasia (BPH) Drugs Manufacturer Market Share in 2017
3.4 Market Competition Trend
4 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Analysis by Regions
4.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Market Share by Regions
4.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales and Market Share by Regions (2013-2018)
4.1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Market Share by Regions (2013-2018)
4.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
4.3 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
4.4 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
4.5 South America Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
4.6 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
5 North America Benign Prostatic Hyperplasia (BPH) Drugs by Countries
5.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Market Share by Countries
5.1.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales and Market Share by Countries (2013-2018)
5.1.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Market Share by Countries (2013-2018)
5.2 United States Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
5.3 Canada Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
5.4 Mexico Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
6 Europe Benign Prostatic Hyperplasia (BPH) Drugs by Countries
6.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Market Share by Countries
6.1.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales and Market Share by Countries (2013-2018)
6.1.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Market Share by Countries (2013-2018)
6.2 Germany Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
6.3 UK Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
6.4 France Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
6.5 Russia Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
6.6 Italy Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
7 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs by Countries
7.1 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Market Share by Countries
7.1.1 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales and Market Share by Countries (2013-2018)
7.1.2 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Market Share by Countries (2013-2018)
7.2 China Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
7.3 Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
7.4 Korea Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
7.5 India Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
7.6 Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
8 South America Benign Prostatic Hyperplasia (BPH) Drugs by Countries
8.1 South America Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Market Share by Countries
8.1.1 South America Benign Prostatic Hyperplasia (BPH) Drugs Sales and Market Share by Countries (2013-2018)
8.1.2 South America Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Market Share by Countries (2013-2018)
8.2 Brazil Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
8.3 Argentina Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
8.4 Colombia Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
9 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs by Countries
9.1 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Market Share by Countries
9.1.1 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales and Market Share by Countries (2013-2018)
9.1.2 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Market Share by Countries (2013-2018)
9.2 Saudi Arabia Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
9.3 UAE Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
9.4 Egypt Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
9.5 Nigeria Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
9.6 South Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
10 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Segment by Type
10.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Market Share by Type (2013-2018)
10.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales and Market Share by Type (2013-2018)
10.1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Market Share by Type (2013-2018)
10.2 Alpha-Blocker Sales Growth and Price
10.2.1 Global Alpha-Blocker Sales Growth (2013-2018)
10.2.2 Global Alpha-Blocker Price (2013-2018)
10.3 Phosphodiesterase Type-5 Inhibitors Sales Growth and Price
10.3.1 Global Phosphodiesterase Type-5 Inhibitors Sales Growth (2013-2018)
10.3.2 Global Phosphodiesterase Type-5 Inhibitors Price (2013-2018)
10.4 5-Alpha-Reductase Inhibitors Sales Growth and Price
10.4.1 Global 5-Alpha-Reductase Inhibitors Sales Growth (2013-2018)
10.4.2 Global 5-Alpha-Reductase Inhibitors Price (2013-2018)
11 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Segment by Application
11.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2013-2018)
11.2 Men Sales Growth (2013-2018)
11.3 Women Sales Growth (2013-2018)
12 Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast (2018-2023)
12.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Growth Rate (2018-2023)
12.2 Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast by Regions (2018-2023)
12.2.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast (2018-2023)
12.2.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast (2018-2023)
12.2.3 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast (2018-2023)
12.2.4 South America Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast (2018-2023)
12.2.5 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast (2018-2023)
12.3 Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast by Type (2018-2023)
12.3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Type (2018-2023)
12.3.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Share Forecast by Type (2018-2023)
12.4 Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast by Application (2018-2023)
12.4.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Application (2018-2023)
12.4.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Share Forecast by Application (2018-2023)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.1.3 Marketing Channel Future Trend
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
List of Tables and Figures
Figure Benign Prostatic Hyperplasia (BPH) Drugs Picture
Table Product Specifications of Benign Prostatic Hyperplasia (BPH) Drugs
Figure Global Sales Market Share of Benign
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
